Nexalin study shows promising results for memory improvement in Alzheimer's patients
Summary: Nexalin Technology announced positive results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) for mild Alzheimer’s patients. The study showed significant improvements in memory and cognitive function, as measured by standard assessments.
The trial involved 46 patients, with those receiving DIFS showing notable gains in cognitive scores and increased neural activity in the hippocampus. Functional MRI scans indicated enhanced blood flow in this critical memory area.
DIFS was well-tolerated, with only minor side effects reported. Nexalin plans to further explore this technology and its potential as a non-invasive treatment option for Alzheimer’s and other mental health conditions.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings